Please type a plus sign (+) inside this box

NIE 19 7005

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE sons are required to Expond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known					
Application Number 10/757,201					
Filing Date	01-14-2004				
First Named Inventor	ROSSKAMP				
Group Art Unit	1654				
Examiner Name	HEMANT KHANNA				
Attorney Docket Number	USAV2003/0012 - US - NP				

				U.S. PATENT DOCL	JMENTS	
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code² (// known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relavant Passages or Relavant Figures Appear
					 	
			-+			
			$\perp \downarrow \downarrow$			· · · · · · · · · · · · · · · · · · ·
			-++			· · · · · · · · · · · · · · · · · · ·
					 	
	-		- 		+	
						

				FORE	IGN PATENT DOCUMENT	rs		
Examiner	Cite	F	oreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	T 8
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
								$oxed{oxed}$
]
					•			
			-					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->	V

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
-				Application Number 10/757,201			
INF	ORMATIO	N D	ISCLOSURE	Filing Date	01-14-2004		
STATEMENT BY APPLICANT				First Named Inventor	ROSSKAMP		
				Group Art Unit	1654		
	(use as many	sheet	s as necessary)	Examiner Name	HEMANT KHANNA	_	
Sheet	2	of	2	Attorney Docket Number	USAV2003/0012 - US - NP		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2					
	ROSENSTOCK, J., et. al, Basal Insulin Therapy in Type 2 Diabetes: 28-week Comparison of Insulin Glargine (HOE 901) and NPH Insulin, Abstract XP002282639 Medline Diabetes Care Apr 2001 VOL.24, NO.4 PP.631-636						
	THOMAS, M., et. al., Evaluation of the Safety, Efficacy and Tolerability of Insulin Glargine in Subjects with Impaired fasting Glucose, Impaired Glucose Tolerance or New-Onset Type 2 Diabetes, Abstract Biosis/Biosis Vol.52, No.Supplement 1, 2003 pp. A451-A452 XP002282638						
	TURNER, R., et. al. Beta-Cell function Improved by Supplementing Basal Insulin Secretion in Mild Diabetes, British Medical Journal 22 May1976, Vol.1, No.6020 pp.1252-1254 XP009031347						
	· .						
		Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ROSENSTOCK, J., et. al, Basal Insulin Therapy in Type 2 Diabetes: 28-week Comparison of Insulin Glargine (HOE 901) and NPH Insulin, Abstract XP002282639 Medline Diabetes Care Apr 2001 VOL.24, NO.4 PP.631-636 THOMAS, M., et. al., Evaluation of the Safety, Efficacy and Tolerability of Insulin Glargine in Subjects with Impaired fasting Glucose, Impaired Glucose Tolerance or New-Onset Type 2 Diabetes, Abstract Biosis/Biosis Vol.52, No.Supplement 1, 2003 pp. A451-A452 XP002282638 TURNER, R., et. al. Beta-Cell function Improved by Supplementing Basal Insulin Secretion in Mild Diabetes,					

Examiner		Date	04/06/2007
Signature	/Hemant Khanna/	Considered	04/00/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.